Welcome to LookChem.com Sign In|Join Free

CAS

  • or

147021-89-4

Post Buying Request

147021-89-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

147021-89-4 Usage

General Description

4-Bromo-3-nitrobenzene-1,2-diamine is a chemical compound that is used in various industrial and research applications. It is a derivative of benzene with two amine groups and bromine and nitro substituents. 4-Bromo-3-nitrobenzene-1,2-diamine is commonly used in the synthesis of other organic compounds and as a building block for pharmaceuticals, dyes, and other chemical products. Its properties and reactivity make it valuable for the development of new materials and compounds in various fields. Additionally, 4-Bromo-3-nitrobenzene-1,2-diamine may also have potential applications in the fields of medicine and biotechnology due to its unique structure and properties. Overall, this chemical compound plays an important role in the advancement of scientific research and the development of new technologies.

Check Digit Verification of cas no

The CAS Registry Mumber 147021-89-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,7,0,2 and 1 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 147021-89:
(8*1)+(7*4)+(6*7)+(5*0)+(4*2)+(3*1)+(2*8)+(1*9)=114
114 % 10 = 4
So 147021-89-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H6BrN3O2/c7-3-1-2-4(8)5(9)6(3)10(11)12/h1-2H,8-9H2

147021-89-4Downstream Products

147021-89-4Relevant articles and documents

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

Keana,Kher,Sui Xiong Cai,Dinsmore,Glenn,Guastella,Huang,Ilyin,Lu,Mouser,Woodward,Weber

, p. 4367 - 4379 (2007/10/02)

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 147021-89-4